Using post-transplant cyclophosphamide and ATG for blood cancer transplants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of post-transplant cyclophosphamide and anti-thymocyte globulin (ATG) as a prophylactic treatment to prevent graft-versus-host disease (GVHD) in patients undergoing hematopoietic stem cell transplantation. The study focuses on patients with acute leukemia, myelodysplastic syndromes, and lymphomas who are receiving related or unrelated HLA-compatible transplants. It aims to evaluate the effectiveness of this approach compared to traditional calcineurin inhibitors, which have a poorer toxicity profile. The trial is designed as a prospective, two-arm, non-randomized study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with (1) acute leukemia in first or second remission; (2) myelodysplasia with less than 20% blasts; (3) Hodgkin's or non-Hodgkin's lymphoma, in partial remission after salvage therapy
* Who will receive a related or unrelated, HLA-compatible transplant;
* Who is a transplant candidate with FluMel, FluTBI, CyTBI, BuCy or BuFlu conditioning;
* Peripheral blood source;
* Age between 18 and 60 years.

Exclusion Criteria:

\- Hepatic dysfunction (transaminases x2 the normal value)

Where it's running

• Instituto Nacional de Cancer
  Rio de Janeiro, Rio de Janeiro, Brazil Recruiting

Study contacts

• Principal investigator: Leonardo J Arcuri, MD, PhD — Instituto Nacional de Cancer
• Study coordinator: Leonardo J Arcuri, MD, PhD
• Email: leonardojavier@gmail.com
• Phone: +5521981334715

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Vitamin A and D supplementation for patients undergoing allogeneic hematopoietic transplantation

  This study is testing if giving high doses of vitamins A and D before a stem cell transplant can help patients with certain blood cancers have fewer complications like infections and graft-versus-host disease.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06508099

• Vaccination to prevent CMV infection in stem cell transplant patients

  This study is testing a new vaccine to see if it can help prevent CMV infections in patients receiving stem cell transplants from related donors.

  Recruiting at 3 sites Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06059391

• Using cord blood transplant and chemotherapy to treat high-risk blood cancers

  This study is testing if combining umbilical cord blood transplants with certain chemotherapy treatments can help people with high-risk blood cancers do better and have fewer side effects.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06013423

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.